Protocol Ledger

NCT05442775 · Phase III · TERMINATED

A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

Interventional Phase III clinical trial protocol NCT05442775 sponsored by Cytokinetics in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-08-04 Enrollment: 71 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05442775
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)71 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05442775
Protocol FieldVerified Registry Value
NCT IdentifierNCT05442775
Consolidated Lead SponsorCytokinetics
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment71 participants (ACTUAL)
Registered Start Date2022-08-04
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05442775
Hospital Research SiteLocationSite Profile
UCI Health and Chao Family Comprehensive Cancer CenterOrange, CAOpen Hospital Dossier ->
University of Colorado Anschutz Medical CampusAurora, COOpen Hospital Dossier ->
Mayo Clinic FloridaJacksonville, FLOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI